Atopic dermatitis in infancy

[1] [2] [3] [11]

Meet the patient

A 7-month-old is brought in scratching his cheeks and scalp raw, waking every hour, and feeding poorly for three weeks. His cheeks are erythematous, dry, crusted, and excoriated; the extensors of his arms are involved; the napkin area is conspicuously spared. His mother has asthma, and she is convinced a food is causing it and wants to cut out dairy.[1][2]

Three exam questions are now live and the candidate must answer all three: is this atopic dermatitis or a mimic? (itch and distribution decide it), what is the foundation of treatment? (emollients, not elimination diet), and what would make this an emergency tonight? (punched-out erosions with fever — eczema herpeticum). Hold those three and the topic falls into place.[1]

What it is — and the one word that makes the diagnosis

Atopic dermatitis is a chronic relapsing inflammatory skin disease defined by pruritus, typical morphology and age-related distribution, and a chronic or chronically relapsing course, often with personal or family atopy. In infancy — onset usually in the first year — lesions favour the face, scalp, trunk, and extensor surfaces; later childhood shifts toward the flexures. Diagnosis is clinical; no laboratory confirms typical disease.[1][2][4]

The one word is itch. A dry, erythematous infant who is scratching, irritable, and sleepless is your disease; a smiling, well-grown baby with a greasy yellow scalp crust who does not scratch is seborrhoeic dermatitis, a different condition with a different prognosis. Examiners listen for that distinction before anything else.[2]

Classification and the distribution clock

The distribution clock is the highest-yield distribution fact in the topic. Infancy sits on the face, scalp, and extensors; childhood migrates to the antecubital and popliteal fossae, wrists, and ankles; adolescence and adulthood settle on the flexures, hands, and head and neck. An "infantile AD" case that is purely flexural should make you pause; an adult with cheek-predominant disease may have head-and-neck variant AD or contact dermatitis.[1]

Epidemiology — common, familial, and barrier-driven

AD affects a substantial minority of children worldwide — often cited around 15 to 20 percent in high-prevalence settings — and many cases begin in infancy. Risk factors are a family history of atopy, FLG loss-of-function variants, urban environments, and skin barrier stressors. Not every infant with an FLG mutation develops AD, and not every AD infant carries one: barrier failure is multifactorial.[1][4][5][6]

[1]

Pathophysiology — three pillars and an itch that feeds itself

Three interlocking pillars drive infantile AD: barrier failure, type 2 inflammation, and microbial dysbiosis. Each pillar is also a treatment target, which is why the paragraph matters clinically and not just biochemically.[1]

Epidermal barrier dysfunction sits at the foundation — reduced filaggrin and natural moisturising factor, lipid abnormalities, and raised transepidermal water loss. The landmark genetic risk factor is FLG loss-of-function (Palmer and colleagues, 2006): carriers lose filaggrin, the skin dries, allergens and microbes walk in. But barrier failure is broader than FLG alone.[5][6]

Type 2 inflammation sits above the broken barrier — interleukin-4 and interleukin-13 drive both barrier damage and inflammation, and interleukin-31 is the itch cytokine. Microbial dysbiosis completes the triangle: Staphylococcus aureus colonisation amplifies inflammation and flares. Infant AD skin has age-specific molecular features distinct from adult AD, which matters for therapeutic targeting and natural history.[1][4][7]

The itch–scratch cycle is the engine. Scratching mechanically wrecks the barrier, drives more inflammation, invites more Staph, and generates more itch — a positive feedback loop that explains why interrupting itch (emollient, anti-inflammatory, antihistamine for sleep) changes the disease, not just the symptom.[1]

Clinical presentation — what to look for, and the napkin clue

Intense pruritus — scratching, irritability, sleep loss — is mandatory for the diagnosis. The lesions are erythematous, dry, scaly, excoriated patches on the cheeks, forehead, and scalp, the extensors of arms and legs, and the trunk. Xerosis is generalised; Dennie–Morgan lines and other atopic stigmata may appear with time.[2]

The napkin area is often relatively spared — and that single clue separates infantile AD from seborrhoeic and candidal napkin disease, which love the folds. Secondary crusting, oozing, and pustules point to bacterial superinfection; severe disease may approach erythroderma. Failure to thrive, erythroderma, or recurrent severe infection should reset the differential toward immunodeficiency.[1]

Differential — the four mimics, each with a one-line discriminator

[1]

The discriminator line: itch separates atopic from seborrhoeic; the napkin area separates atopic from napkin candidiasis. A smiling, well baby with greasy cradle cap is seborrhoeic; do not label him atopic and burden the family with a chronic-disease framework.[1]

Bedside assessment — measure itch, growth, and the caregiver

Assess itch and sleep, extent, infection signs, growth, caregiver stress, and prior steroid or antibiotic exposure. Severity language (mild, moderate, severe) and scores (EASI and SCORAD concepts) support communication and trial literacy even when formal scoring is not done at every visit. A failing-to-thrive infant with severe eczema is not a routine case — escalate the workup.[2][12]

Investigations — usually none, sometimes decisive

Most typical mild-to-moderate infantile AD needs no test at all. A skin swab is warranted for recurrent crusting or pustules. Allergy evaluation belongs only when the history suggests IgE-mediated food reactions or the disease is refractory — avoid shotgun panels that drive harmful elimination diets.[2][8]

Biopsy and broader workup are reserved for the atypical — purpuric, ulcerative, or systemically unwell infants where Langerhans cell histiocytosis, primary immunodeficiency, or another genodermatosis is in play. The cost of missing Netherton or severe combined immunodeficiency is far higher than the cost of a biopsy.[2]

Management — the foundation every infant gets

The mantra: emollients first, then site-appropriate anti-inflammatory, then treat infection, then escalate. Every infant gets the foundation, regardless of severity.[3][12]

1. Education — chronic relapsing course; a written flare plan the family can follow.[3]
2. Emollients, liberally and frequently — the cornerstone of barrier repair, applied often and generously.[3][9][12]
3. Bathing — short lukewarm baths, gentle cleansers, emollient after pat-drying.
4. Trigger minimisation — wool, harsh soaps, heat, saliva; individualise food only with a clear history.[3][8]

Topical anti-inflammatory therapy — least potent, shortest time, then step down

Use the least potent agent that controls the disease, for the shortest effective time, then step down — while continuing emollients throughout. Site dictates potency: the thin skin of the face, neck, and flexures gets a low-potency topical corticosteroid (hydrocortisone-class teaching) or a topical calcineurin inhibitor when age-licensed and indicated; the trunk and limbs may take a mild-to-moderate potency agent for flares.[3][9]

Wet wraps belong in severe flares and only under experienced supervision — they increase corticosteroid absorption and can cause systemic effects if misused. A network meta-analysis confirms that several effective topical classes exist; choice turns on site, age, cost, and access rather than on a single "best" drug. European and AAD-aligned pathways emphasise proactive maintenance — low-frequency topical anti-inflammatory to frequently relapsing sites after control is induced.[3][12]

Infection and the emergency — eczema herpeticum

Treat clinically infected AD with the appropriate topical or systemic antimicrobial plus anti-inflammatory and barrier care. But the entity that must never be missed is eczema herpeticum: monomorphic punched-out erosions with fever and malaise, a dermatological emergency that earns an urgent systemic aciclovir or valaciclovir pathway and specialist care. Do not escalate steroids alone — that delays the antiviral the child actually needs.[10]

Phototherapy and systemic therapy — when topical is not enough

Phototherapy is rarely used in young infants for practical and safety reasons. Severe, refractory disease needs paediatric dermatology for systemic options. Dupilumab has demonstrated efficacy and acceptable safety signals in young children — including open-label extension data in ages 6 months to 5 years — and is a landmark targeted option where regulatory labelling and access allow.[11] JAK inhibitors and conventional immunosuppressants remain specialist tools with age-specific labelling — do not invent doses outside licensed specialist practice.[8][12]

Feeding, families, and the atopic march

Breastfeeding is encouraged per general paediatric guidance; maternal diet restriction is not routine without a specialist indication. The trap that harms infants is the unsupervised elimination diet — multi-food restriction without a proven allergy risks malnutrition and failure to thrive, a major and entirely preventable pitfall. Routine immunisations are not withheld because of AD.[8]

Screen for primary immunodeficiency when severe refractory AD coexists with infections, diarrhoea, or poor growth. And counsel the family on the atopic march: infant AD raises the trajectory for food allergy, asthma, and allergic rhinitis, though not every child marches. Sleep loss and parental mental health are part of the disease burden, not side issues.[1][4]

Prognosis — many improve, a minority persist

Many infants improve through childhood, but a substantial minority persist or relapse, and FLG-related disease may be the more persistent phenotype. Provide follow-up proportional to severity, with clear escalation instructions for infection or herpeticum, and reassure honestly: most do well, but the condition is chronic and relapsing, not cured by a single cream.[5][6]

Evidence, guidelines, and where regions differ

The anchor documents examiners cite are the Lancet overviews (Langan; Weidinger),[1][4] the AAD diagnosis and topical sections (Eichenfield),[2][3] the European consensus (Wollenberg),[12] the AAAAI or ACAAI Joint Task Force 2023 GRADE-informed guidance (Chu),[8] the topical network meta-analysis (Chu),[9] and the early-life dupilumab extension data (Paller).[11] NICE and UK, IADVL, and ANZ pathways share the emollient-first logic with regional formulary differences for topical calcineurin inhibitors and biologic access.

Exam pearls

[1] [2] [5]

Ward-round test

A 7-month-old with known AD presents with fever and monomorphic punched-out erosions overlying his eczema. What is this, and what is the first step?

Eczema herpeticum — a dermatological emergency. Do not escalate topical steroids. Start an urgent systemic aciclovir or valaciclovir pathway and involve specialist care. The clue is monomorphic punched-out erosions with systemic upset in an infant with AD.

[10]

A mother wants to cut dairy, egg, and wheat from her eczematous infant's diet to find the cause. What is the risk?

Malnutrition and failure to thrive from an unsupervised multi-food elimination diet. Test and restrict diet only with a clear clinical indication and dietetic support. The foundation of treatment is emollients and site-appropriate topical anti-inflammatories, not elimination.

[8]

A 3-month-old has a greasy yellow crust on the scalp and eyebrows, scale in the folds and napkin folds, and is a smiling, well-grown baby who does not scratch. Diagnosis?

Infantile seborrhoeic dermatitis (cradle cap), not atopic dermatitis. The discriminator is the absence of itch. It is usually self-limited over months; gentle cleansing and emollient suffice. Family atopy and an itchy, sleepless infant would point the other way.

[1]

A 6-month-old with severe, refractory, erythrodermic eczema is failing to thrive and has recurrent infection. What must you exclude?

Primary immunodeficiency (for example, severe combined immunodeficiency, Wiskott–Aldrich, hyper-IgE syndrome) and Netherton syndrome. Severe refractory AD with failure to thrive, erythroderma, or recurrent infection is not routine eczema — escalate to biopsy, immunology, and genetics.

[1]

References

1. [1]Langan SM, Irvine AD, Weidinger S. Atopic dermatitis Lancet, 2020.PMID 32738956
2. [2]Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis J Am Acad Dermatol, 2014.PMID 24290431
3. [3]Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies J Am Acad Dermatol, 2014.PMID 24813302
4. [4]Weidinger S, Novak N. Atopic dermatitis Lancet, 2016.PMID 26377142
5. [5]Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis Nat Genet, 2006.PMID 16550169
6. [6]Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease Ann Allergy Asthma Immunol, 2020.PMID 31622670
7. [7]Renert-Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults J Allergy Clin Immunol, 2021.PMID 33453290
8. [8]Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations Ann Allergy Asthma Immunol, 2024.PMID 38108679
9. [9]Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials J Allergy Clin Immunol, 2023.PMID 37678572
10. [10]Traidl S, Roesner L, Zeitvogel J, et al. Eczema herpeticum in atopic dermatitis Allergy, 2021.PMID 33844308
11. [11]Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study Am J Clin Dermatol, 2024.PMID 38743155
12. [12]Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I J Eur Acad Dermatol Venereol, 2018.PMID 29676534